Order Code DHEA-Sulfate SO Dehydroepiandrosterone Sulfate, Serum
Additional Codes
Epic Order ID LAB4110IA
Specimen Required
Collection Container/Tube:
Preferred: Serum gel
Acceptable: Red top
Submission Container/Tube: Plastic vial
Specimen Volume: 0.6 mL
Collection Instructions: Centrifuge and aliquot serum into a plastic vial.
Secondary ID
113595Useful For
Diagnosis and differential diagnosis of hyperandrogenism (in conjunction with measurements of other sex steroids)
An adjunct in the diagnosis of congenital adrenal hyperplasia
Diagnosis and differential diagnosis of premature adrenarche
Method Name
Immunoenzymatic Assay
Reporting Name
Dehydroepiandrosterone Sulfate, SSpecimen Type
SerumSpecimen Minimum Volume
0.5 mL
Specimen Stability Information
Specimen Type | Temperature | Time |
---|---|---|
Serum | Refrigerated (preferred) | 14 days |
Frozen | 30 days | |
Ambient | 7 days |
Reject Due To
Gross hemolysis | Reject |
Gross lipemia | OK |
Gross icterus | OK |
Clinical Information
Dehydroepiandrosterone (DHEA) is the principal human C-19 steroid. DHEA has very low androgenic potency but serves as the major direct or indirect precursor for most sex steroids. DHEA is secreted by the adrenal gland and production is at least partly controlled by adrenocorticotropic hormone. The bulk of DHEA is secreted as a 3-sulfoconjugate (DHEA-S). Both hormones are albumin bound, but binding of DHEA-S is much tighter. In gonads and several other tissues, most notably skin, steroid sulfatases can convert DHEA-S back to DHEA, which can then be metabolized to stronger androgens and to estrogens.
During pregnancy, DHEA-S and its 16-hydroxylated metabolites are secreted by the fetal adrenal gland in large quantities. They serve as precursors for placental production of the dominant pregnancy-related estrogen, estriol. Within weeks after birth, DHEA-S levels fall by 80% or more and remain low until the onset of adrenarche. Adrenarche is a poorly understood phenomenon peculiar to higher primates, which is characterized by a gradual rise in adrenal androgen production. It precedes puberty but is not causally linked to it. Early adrenarche is not associated with early puberty or with any reduction in final height or overt androgenization and is generally regarded as a benign condition, not needing intervention. However, girls with early adrenarche may be at increased risk of polycystic ovarian syndrome as adults, and some boys may develop early penile enlargement.
Following adrenarche, DHEA-S levels increase until the age of 20, up to maximum levels roughly comparable to that observed at birth. Levels then decline over the next 40 to 60 years to around 20% of peak levels. The clinical significance of this age-related drop is unknown and trials of DHEA-S replacement in the elderly have not produced convincing benefits. However, in young and old patients with primary adrenal failure, the addition of DHEA-S to corticosteroid replacement has been shown in some studies to improve mood, energy, and sex drive.
Elevated DHEA-S levels can cause symptoms or signs of hyperandrogenism in women. Men are usually asymptomatic, but through peripheral conversion of androgens to estrogens can occasionally experience mild estrogen excess. Most mild to moderate elevations in DHEA-S levels are idiopathic. However, pronounced elevations of DHEA-S may be indicative of androgen-producing adrenal tumors. In small children, congenital adrenal hyperplasia (CAH) due to 3 beta-hydroxysteroid deficiency is associated with excessive DHEA-S production. Lesser elevations may be observed in 21-hydroxylase deficiency (the most common form of CAH) and 11 beta-hydroxylase deficiency. By contrast, steroidogenic acute regulatory protein or 17 alpha-hydroxylase deficiencies are characterized by low DHEA-S levels.
An initial workup in adults might also include total and bioavailable testosterone (TTBS / Testosterone, Total and Bioavailable, Serum) measurements. Depending on results, this may be supplemented with measurements of sex hormone-binding globulin (SHBG /Sex Hormone-Binding Globulin [SHBG], Serum) and occasionally other androgenic steroids (eg, 17-hydroxyprogesterone).
Reference Values
MALES
1-14 days: DHEA-S levels in newborns are very elevated at birth but will fall to prepubertal levels within a few days.
Tanner Stages*
Mean |
Age |
Reference Range (mcg/dL) |
Stage I |
>14 days |
11-120 |
Stage II |
11.5 years |
14-323 |
Stage III |
13.6 years |
5.5-312 |
Stage IV |
15.1 years |
29-412 |
Stage V |
18.0 years |
104-468 |
*Puberty onset (transition from Tanner stage I to Tanner stage II) occurs for boys at a median age of 11.5 (±) 2 years. For boys, there is no proven relationship between puberty onset and body weight or ethnic origin. Progression through Tanner stages is variable. Tanner stage V (adult) is usually reached by age 18.
18-30 years: 105-728 mcg/dL
31-40 years: 57-522 mcg/dL
41-50 years: 34-395 mcg/dL
51-60 years: 20-299mcg/dL
61-70 years: 12-227 mcg/dL
≥71 years: 6.6-162 mcg/dL
FEMALES
1-14 days: DHEA-S levels in newborns are very elevated at birth but fall to prepubertal levels within a few days.
Tanner Stages*
Mean |
Age |
Reference Range (mcg/dL) |
Stage I |
>14 days |
16-96 |
Stage II |
10.5 years |
22-184 |
Stage III |
11.6 years |
11-296 |
Stage IV |
12.3 years |
17-343 |
Stage V |
14.5 years |
57-395 |
*Puberty onset (transition from Tanner stage I to Tanner stage II) occurs for girls at a median age of 10.5 (±) 2 years. There is evidence that it may occur up to 1 year earlier in obese girls and in African American girls. Progression through Tanner stages is variable. Tanner stage V (adult) is usually reached by age 18.
18-30 years: 83-377 mcg/dL
31-40 years: 45-295 mcg/dL
41-50 years: 27-240 mcg/dL
51-60 years: 16-195 mcg/dL
61-70 years: 9.7-159
≥71 years: 5.3-124 mcg/dL
Clinical Reference
1. Sciarra F, Tosti-Croce C, Toscano V. Androgen-secreting adrenal tumors. Minerva Endocrinol 1995;20:63-68
2. Young WF J.: Management approaches to adrenal incidentalomas-a view from Rochester, Minnesota. Endocrinol Metab Clin North Am 2000;21:671-696
3. Ibanez L, DiMartino-Nardi J, Potau N, Saenger P. Premature adrenarche-normal variant or forerunner of adult disease? Endocrine Reviews 2001;40:1-16
4. Collett-Solberg P. Congenital adrenal hyperplasia: from genetics and biochemistry to clinical practice, part I. Clin Pediatr 2001;40:1-16
5. Allolio B, Arlt W. DHEA treatment: myth or reality? Trends Endocrinol Metab 2002;13:288-294
6. Salek FS, Bigos KL, Kroboth PD. The influence of hormones and pharmaceutical agents on DHEA and DHEA-S concentrations: a review of clinical studies. J Clin Pharmacol 2002;42:247-266
7. Elmlinger MW, Kuhnel W, Ranke MB: Reference ranges for serum concentrations of lutropin (LH), follitropin (FSH), estradiol (E2), prolactin, progesterone, sex hormone binding globulin (SHBG), dehydroepiandrosterone sulfate (DHEA-S), cortisol and ferritin in neonates, children, and young adults. Clin Chem Lab Med 2002;40(11):1151-1160
8. Charoensri S, Chailurkit L, Muntham D, Bunnag P. Serum dehydroepiandrosterone sulfate in assessing the integrity of the hypothalamic-pituitary-adrenal axis. J Clin Transl Endocrinol. 2017 Jan 31;7:42-46. doi: 10.1016/j.jcte.2017.01.001
9. Al-Aridi R., Abdelmannan D., Arafah B.M. Biochemical diagnosis of adrenal insufficiency: the added value of dehydroepiandrosterone sulfate measurements. Endocr Pract. 2011;17(2):261–270
10. Bancos I., Hahner S., Tomlinson J., Arlt W. Diagnosis and management of adrenal insufficiency. Lancet Diabetes Endocrinol. 2015;3(3):216–226
Day(s) Performed
Monday through Friday
Report Available
1 to 3 daysPerforming Laboratory

Test Classification
This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.CPT Code Information
82627
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
DHES1 | Dehydroepiandrosterone Sulfate, S | 2191-5 |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
DHES1 | Dehydroepiandrosterone Sulfate, S | 2191-5 |
Forms
If not ordering electronically, complete, print, and send a General Request (T239) with the specimen.